A study of pre- and post-treatment hematologic markers of immune response in patients undergoing radiotherapy for soft tissue sarcoma.

Autor:	Ku E; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States., Harada G; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States., Lee G; School of Medicine, University of California Irvine, Irvine, CA, United States., Munjal A; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States., Peterson N; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States., Park J; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States., Chow W; Department of Hematology/Oncology, University of California Irvine, Orange, CA, United States., Stitzlein R; Department of Orthopedic Surgery, University of California Irvine, Orange, CA, United States., Limoli C; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States., Harris J; Department of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Oct 03; Vol. 14, pp. 1392705. Date of Electronic Publication: 2024 Oct 03 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1392705
Abstrakt:	Introduction: This study investigates the impact of pre- and post-treatment hematologic markers, specifically neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), on treatment outcomes in soft tissue sarcoma (STS) patients undergoing radiation therapy (RT). Methods: Data from 64 patients who underwent RT for curative management of STS were reviewed. Pre-RT and post-RT hematologic measures were evaluated for associations with survival outcomes. A normal tissue complication probability (NTCP) curve for predicting ΔPLR ≥ 75 was modeled using a probit function. Results: Elevated baseline NLR was associated with worse overall survival (OS) and disease-free survival (DFS), while elevated PLR was associated with worse DFS. Post-RT, elevated PLR was linked to worse OS and DFS. Increasing PLR change post-RT was associated with worse OS and DFS. Receiver operating characteristics analysis determined ΔPLR ≥ 75 to be a robust cutoff associated with worse DFS. Bone V10Gy ≥362 cc corresponded to a 50% risk of developing ΔPLR ≥ 75. Discussion: These results suggest that hematologic markers could serve as prognostic biomarkers in both pre- and post-treatment settings for STS patients undergoing RT. Future studies can consider using bone V10Gy < 362 cc as a potential cutoff to reduce the risk of increased PLR after RT. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Ku, Harada, Lee, Munjal, Peterson, Park, Chow, Stitzlein, Limoli and Harris.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu